Pharmicell Co (XKRX:005690) Accounts Payable & Accrued Expense : ₩4,948 Mil (As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Accounts Payable & Accrued Expense?

Pharmicell Co's quarterly accounts payable & accrued expense declined from Sep. 2023 (₩4,191 Mil) to Dec. 2023 (₩3,245 Mil) but then increased from Dec. 2023 (₩3,245 Mil) to Mar. 2024 (₩4,948 Mil).

Pharmicell Co's annual accounts payable & accrued expense increased from Dec. 2021 (₩1,932 Mil) to Dec. 2022 (₩4,237 Mil) but then declined from Dec. 2022 (₩4,237 Mil) to Dec. 2023 (₩3,245 Mil).

Pharmicell Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Pharmicell Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Accounts Payable & Accrued Expense Chart

Pharmicell Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,356.98

2,430.91

1,932.00

4,236.86

3,245.03

Pharmicell Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															4,586.43	3,273.93	4,190.53	3,245.03	4,948.37

Pharmicell Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Pharmicell Co (XKRX:005690) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines